Citrus Pectin Can Slow Progression of Prostate Cancer
something as simple as eating oranges protect men from prostate cancer?
No, but according to a new study published in The Prostate, patients
taking modified citrus pectin, a carbohydrate derived from the peel
of citrus fruit, may slow the progression of prostate cancer. Phase
II clinical research published in The Prostate (“Using Splines
to Detect Changes in PSA Doubling Times,” February 1, 2003),
validated a new statistical method of evaluating the effectiveness
of any nutritional supplement or drug. While the statistical method
was peer-reviewed, the methods and results of the clinical trial
were not. However all the preliminary data was presented and from
a clinical perspective, the results, according to medical researchers,
are very encouraging. This data indicates that PectaSol® Modified
Citrus Pectin significantly slowed the progression of prostate cancer
as indicated by the slowing of PSA progression. Patients with slower
PSA progression live longer and have a better chance of overcoming
is based on a carefully controlled study conducted by researchers
Prostate Cancer Research Institute and Healing
Touch Oncology that included one year of treatment and follow up
time. All of the patients selected for the study showed biochemical
PSA failure after primary treatment, i.e. radical prostatectomy,
radiation or cryosurgery. Patients were provided with 15 grams
of PectaSol® Modified Citrus Pectin (EcoNugenics®, Inc.
Santa Rosa, Calif.) per day in three divided oral doses. Modified
Citrus Pectin was shown to slow the progression of prostate cancer
in 9 out of 12 patients as measured by changes in PSA (Prostate
Specific Antigen) levels.
“The results of The Prostate study are very encouraging.
It shows that PectaSol Modified Citrus Pectin works on prostate
cancer,” said Isaac Eliaz, MD, a leader in the field of integrative
medicine. Dr. Eliaz maintains a private practice in northern California,
focusing primarily on treating cancer patients and is the founder
of EcoNugenics, the dietary supplement company that provided PectaSol
for the study. Dr. Eliaz also holds two patents (nos. 6,462,029
and 6,274,566) developing a unique composition of modified citrus
pectin for treatment of diseases.
“This is the second human clinical trial that has demonstrated
the effectiveness of PectaSol MCP in slowing the progression of
prostate cancer” Dr. Eliaz said. The earlier Phase I clinical
study conducted in 1999 by Stephen Strum, MD and Mark Scholz, MD
(presented at the International Conference on Diet and Prevention
of Cancer) demonstrated that Modified Citrus Pectin significantly
lengthened the PSA doubling time in four of seven patients.
a prostate cancer oncologist, is the author of the recently published
A Primer on Prostate Cancer: The Empowered
Patient's Guide. “Modified Citrus Pectin is a natural substance,
it’s non-toxic and it has been shown to slow down the progression
of prostate cancer,” said Dr. Stephen Strum. “I recommend
MCP selectively to patients who have a high risk of recurrence
of prostate cancer after any primary treatment. I also recommend
MCP for those who have shown a slow, persistent rise of PSA levels
that is consistent with established prostate cancer recurrence,” Strum
research suggests that MCP can be used for a wide range of cancers.
in vivo research published last month in the Journal
of the National Cancer Institute (Pratima Nangia-Makker, et. al., “Inhibition
of human cancer cell growth and metastasis in nude mice by oral
intake of modified citrus pectin,” December 18, 2002;94:1854-1862)
demonstrates that modified citrus pectin reduces tumor growth,
angiogenesis, and metastasis in tumors that contain galectin-3
molecules, including breast and colon cancer.
Citrus Pectin is a complex carbohydrate found in the peel of citrus
fruit. Modified Citrus Pectin is a carbohydrate that has been altered
to form shorter chain molecules for better absorption through the
digestive tract into the bloodstream. Modified Citrus Pectin has
been shown to reduce cancer metastasis in animal studies, and has
demonstrated cancer cell killing abilities. Cancer cells are known
to have certain cancer specific protein molecules on their surface
that allow it to spread and grow. Modified Citrus Pectin is thought
to bind to galectin-3, a select class of these cancer specific
molecules, preventing the cancer from functioning normally and
causing it to self-destruct.
Prostate cancer is the second leading cause of cancer deaths in
American men. According to the American Cancer Society, approximately
189,000 new cases of prostate cancer were reported in 2002. More
than 30,000 men died of prostate cancer last year compared to approximately
40,000 deaths of women due to breast cancer.
Source: American Nutraceutical Association
to Nutraceuticals Reference Section
to Health Main Reference Category
Return to NEWSdial.com